中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.01 seconds)

    MENISCAL IMPLANT OF HYALURONIC ACID DERIVATIVES FOR TREATMENT OF MENISCAL DEFECTS
    1.
    发明申请
    MENISCAL IMPLANT OF HYALURONIC ACID DERIVATIVES FOR TREATMENT OF MENISCAL DEFECTS 审中-公开
    用于治疗男性缺陷的羟丙酸衍生物的男性植入物

    公开(公告)号：WO2007070546A3

    公开(公告)日：2007-08-16

    申请号：PCT/US2006047473

    申请日：2006-12-13

    Applicant: ANIKA THERAPEUTICS INC ,  SADOZAI KHALID K ,  TOTH CAROL A

    Inventor： SADOZAI KHALID K ,  TOTH CAROL A

    IPC: A61F2/38 ,  A61K31/728 ,  A61L27/20 ,  A61P19/02

    CPC classification number: A61L27/3843 ,  A61K9/0024 ,  A61K9/06 ,  A61K31/573 ,  A61K31/728 ,  A61K31/729 ,  A61K35/28 ,  A61K35/32 ,  A61K38/1841 ,  A61K47/36 ,  A61L27/20 ,  A61L27/227 ,  A61L27/3817 ,  A61L27/3834 ,  A61L27/48 ,  A61L27/52 ,  A61L27/56 ,  A61L2430/06 ,  C08L5/08 ,  A61K2300/00

    Abstract: A composite for treating an articular defect includes a hyaluronic acid derivative; and at least one member of the group consisting of a cell, a cellular growth factor and a cellular differentiation factor, which is impregnated in, or coupled to. the hyaluronic acid derivative. In one embodiment, carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the hyaluronic acid derivative is prepared by reacting an uncrosslinked hyaluronic acid with a biscarbodimide in the presence of a pH buffer in a range of between about 4 and about 8. The composite can be used for regenerating or stimulating regeneration of meniscal tissues in a subject in need thereof.

    Abstract translation: 用于治疗关节缺损的复合物包括透明质酸衍生物; 以及由细胞，细胞生长因子和细胞分化因子组成的组中的至少一个成员，其被浸渍或偶联。 透明质酸衍生物。 在一个实施方案中，透明质酸衍生物的羧基官能度各自独立地衍生化为包括N-酰基脲或O-酰基异脲，或N-酰基脲和O-酰基异脲二者。 在另一个实施方案中，透明质酸衍生物通过在约4至约8范围内的pH缓冲剂存在下使未交联的透明质酸与双碳酰亚胺反应来制备。该复合物可用于再生或刺激半月板组织的再生 在有需要的受试者中。

    MENISCAL IMPLANT OF HYALURONIC ACID DERIVATIVES FOR TREATMENT OF MENISCAL DEFECTS
    3.
    发明申请
    MENISCAL IMPLANT OF HYALURONIC ACID DERIVATIVES FOR TREATMENT OF MENISCAL DEFECTS 审中-公开
    透明质酸衍生物半月板移植治疗半月板缺损

    公开(公告)号：WO2007070546A2

    公开(公告)日：2007-06-21

    申请号：PCT/US2006/047473

    申请日：2006-12-13

    Applicant: ANIKA THERAPEUTICS, INC. ,  SADOZAI, Khalid, K. ,  TOTH, Carol, A.

    Inventor： SADOZAI, Khalid, K. ,  TOTH, Carol, A.

    IPC: A61F2/38 ,  A61L27/20 ,  A61K31/728 ,  A61P19/02

    CPC classification number: A61L27/3843 ,  A61K9/0024 ,  A61K9/06 ,  A61K31/573 ,  A61K31/728 ,  A61K31/729 ,  A61K35/28 ,  A61K35/32 ,  A61K38/1841 ,  A61K47/36 ,  A61L27/20 ,  A61L27/227 ,  A61L27/3817 ,  A61L27/3834 ,  A61L27/48 ,  A61L27/52 ,  A61L27/56 ,  A61L2430/06 ,  C08L5/08 ,  A61K2300/00

    Abstract: A composite for treating an articular defect includes a hyaluronic acid derivative; and at least one member of the group consisting of a cell, a cellular growth factor and a cellular differentiation factor, which is impregnated in, or coupled to. the hyaluronic acid derivative. In one embodiment, carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the hyaluronic acid derivative is prepared by reacting an uncrosslinked hyaluronic acid with a biscarbodimide in the presence of a pH buffer in a range of between about 4 and about 8. The composite can be used for regenerating or stimulating regeneration of meniscal tissues in a subject in need thereof.

    Abstract translation: 用于治疗关节缺陷的组合物包括透明质酸衍生物; 和至少一种由细胞，细胞生长因子和细胞分化因子组成的组中的至少一种成分，所述细胞浸润或偶联于细胞生长因子和细胞分化因子。 透明质酸衍生物。 在一个实施方案中，透明质酸衍生物的羧基官能度各自独立地衍生为包括N-酰基脲或O-酰基异脲，或者N-酰基脲和O-酰基异脲二者。 在另一个实施方案中，透明质酸衍生物通过使未交联的透明质酸与双碳二亚胺在pH缓冲剂存在下在约4至约8的范围内反应来制备。该复合材料可用于再生或刺激半月板组织的再生 在有需要的主题。

    CROSSLINKED HYALURONIC ACID COMPOSITIONS FOR TISSUE AUGMENTATION
    4.
    发明申请
    CROSSLINKED HYALURONIC ACID COMPOSITIONS FOR TISSUE AUGMENTATION 审中-公开
    用于组织补充剂的交联羟丙酸组合物

    公开(公告)号：WO2005067994A1

    公开(公告)日：2005-07-28

    申请号：PCT/US2003/041354

    申请日：2003-12-23

    Applicant: ANIKA THERAPEUTICS, INC. ,  SADOZAI, Khalid, K. ,  GOODING, Tamara, B. ,  BUI, Kyle ,  SHERWOOD, Charles, H.

    Inventor： SADOZAI, Khalid, K. ,  GOODING, Tamara, B. ,  BUI, Kyle ,  SHERWOOD, Charles, H.

    IPC: A61L27/52

    CPC classification number: A61K31/24 ,  A61K9/0019 ,  A61K9/0021 ,  A61K9/0024 ,  A61K9/1652 ,  A61K47/36

    Abstract: A hyaluronic acid (HA) composition includes crosslinked, water-insoluble, hydrated HA gel particles. The HA includes crosslinks represented by the following structural formula: HA′-U-R 2 -U- HA′. The variables are defined herein. A method of augmenting tissue in a subject includes inserting a needle into a subject at a location in the subject that is in need of tissue augmentation, wherein the needle is coupled to a syringe loaded with the HA composition, and applying force to the syringe, to deliver the HA composition into the subject. A method of preparing the HA composition, includes forming water-insoluble, dehydrated crosslinked HA particles, separating the water-insoluble, dehydrated particles by average diameter, selecting a subset of particles by average diameter, and hydrating the subset of dehydrated particles with a physiologically compatible aqueous solution. Another method of preparing the crosslinked HA composition includes crosslinking a precursor of the crosslinked HA with a biscarbodiimide in the presence of a pH buffer and dehydrating the crosslinked HA.Also included is a method of augmenting tissue in a subject that is in need of tissue augmentation. A method of stabilizing crosslinked HA includes hydrating water-insoluble, dehydrated crosslinked HA with a physiologically compatible aqueous solution that includes a local anesthetic, wherein the value of storage modulus G' for the stabilized composition is at least about 110% of the value of G' for a non-stabilized composition. Also included is the stabilized HA composition.

    Abstract translation: 透明质酸（HA）组合物包括交联的水不溶性水合HA凝胶颗粒。 HA包括由以下结构式表示的交联：HA'-U-R2-U-HA'。 变量在此定义。 增加受试者中的组织的方法包括在需要组织增大的受试者的位置处将针插入受试者，其中针联接到装有HA组合物的注射器，并向注射器施加力， 将HA组合物输送到受试者。 制备HA组合物的方法包括形成不溶于水的，脱水的交联HA颗粒，将水不溶性脱水颗粒分离成平均直径，通过平均直径选择颗粒子集，并将生理学上的脱水颗粒子集合 相容的水溶液。 制备交联HA组合物的另一种方法包括在pH缓冲剂存在下使双碳二亚胺交联HA的前体，并使交联的HA脱水。还包括增加需要组织增加的受试者中的组织的方法 。 稳定交联HA的方法包括用包含局部麻醉剂的生理相容性水溶液水合非水溶性脱水交联HA，其中稳定化组合物的储能模量G'的值至少为G值的约110％ “为非稳定组合物。 还包括稳定的HA组合物。

Patent Agency Ranking